A Study to Investigate the Safety, Tolerability and Effects of AZD8630 in Healthy Subjects and Subjects With Asthma on Inhaled Corticosteroids and Long-acting Beta-agonists

Asthma Clinical Trial

Official title:

Phase I, Randomised, Blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8630 in Healthy Adult Subjects (Part A) and Adults With Asthma on Medium to High Dose Inhaled Corticosteroids and Long-acting Beta-agonists (Part B)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05110976
• Other study ID #: D6830C00001
• Secondary ID: 2021-004000-18
• Status: Completed
• Phase: Phase 1
• Start date: December 16, 2021
• Est. completion date: August 2, 2023

Study information

• Verified date: August 2023
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a first in human (FIH) clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8630 in healthy adults (Part A) and adult asthma patients on medium to high dose inhaled corticosteroids / Long-acting beta-agonists (Part B)

Description:

The study is divided in 2 parts, A and B. Part A will be conducted in healthy adults, whereas Part B will be conducted in adult asthma patients on medium/high dose inhaled corticosteroids (ICS)/long-acting beta-agonists (LABA) to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of AZD8630 by dry powder inhaler (DPI) administration. Part A includes the assessment of the PK and safety of intravenous (IV) AZD8630. Part A consists of single ascending dose (SAD) and multiple ascending dose (MAD) cohorts in sequential order and Part B will be evaluating multiple dose levels. Part A: This part will consist 4 sub-parts and will include healthy participants and healthy participants of Chinese and Japanese ethnicity. These participants will randomized to receive AZD8630 and to receive placebo. - Sub-Part A1, SAD in healthy participants (one cohort in Sub-Part A1 will receive IV AZD8630 [IV formulation]) - Sub-Part A2, SAD in healthy participants of Chinese and Japanese ethnicity - Sub-Part A3, MAD in healthy participants - Sub-Part A4, MAD in healthy participants of Chinese and Japanese ethnicity Part B: Adult asthma patients will be randomized to one of 3 inhaled dose levels of AZD8630 or placebo. The expected duration of study participation for each participants in the part A is up to 87 days, and each patients in the Part B is up to 70 days.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 170
• Est. completion date: August 2, 2023
• Est. primary completion date: August 2, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

Part A (Healthy participants):

1. Healthy participants aged 18 to 55 years, inclusive:

1. Japanese participants must be aged 20 to 55 years, inclusive

2. Chinese participants must be aged 18 to 45 years, inclusive

2. Females must have a negative serum pregnancy test at the Screening Visit and a negative urine pregnancy test on admission to the Clinical Unit, must not be lactating, and must be of non childbearing potential, confirmed at the Screening Visit

3. Have a body mass index (BMI) between 18 and 30 kg/m^2 inclusive and weigh at least 45 kg.

4. Healthy participant must have a forced expiratory volume in 1 second (FEV1) = 80% of the predicted value regarding age, height, gender, and ethnicity at the Screening Visit.

5. Male participants and their women of childbearing potential partners (WOCPB) should be willing to use highly effective contraception measures and male participants should refrain from donating sperm or fathering a child from the first day of dosing until 3 months after the study Follow up Visit.

6. Part A2 and Part A4 (Chinese population only): Chinese participants must have been born in China, have all parents and grandparents of Chinese origin, and not have lived outside of China for more than 10 years.

7. Part A2 and Part A4 (Japanese population only): Japanese participants must have been born in Japan, have all parents and grandparents of Japanese origin, and not have lived outside of Japan for more than 10 years.

Part B (Participants with Asthma):

1. Male and female including WOCBP participants with asthma aged 18 to 75 years inclusive, with suitable veins for cannulation or repeated venipuncture.

2. Have a BMI between 18 and 35 kg/m^2 inclusive and weigh at least 45 kg.

3. Confirmed physician-led diagnosis of asthma for > 6 months before the Screening Visit.

4. Any of the following assessments within the last 10 years to confirm variable airflow obstruction: Variability between clinic visits: FEV1 > 12% and 200 mL; Response to 4 weeks' anti-inflammatory therapy: FEV1 > 12% and 200 mL; Exercise challenge test: FEV1 fall > 10% and 200mL; Methacholine challenge test: FEV1 = 20% fall at < 8 mg/mL; Indirect challenge test: FEV1 = 15% fall; Or in the screening period: Variability between clinic visits: FEV1 > 12% and 200 mL; Peak expiratory flow rate (PEFR) for 2 weeks during run-in: PEFR average daily variability > 10%.

5. Pre-bronchodilator FEV1 = 40% and < 85% predicted at the Screening Visit.

6. Have a fractional exhaled nitric oxide (FeNO) of = 35 ppb at the Screening Visit and = 30 ppb at randomisation.

7. Asthma Control Questionnaire -5 score of = 0.75 and = 3.0 at screening.

8. During 7 consecutive days within screening, immediately prior to randomisation

demonstrates = 65% adherence to each of the following:

1. Once daily home FeNO

2. Twice daily home spirometry measurements

3. Twice daily entries in the eDiary

9. Females must have a negative serum pregnancy test at the Screening Visit. Additionally, WOCBP must have a negative urine pregnancy test at Visit 2 (prior to randomisation) and must not be lactating.

10. Male participants and their WOCBP partners should be willing to use highly effective contraception measures and male participants should refrain from donating sperm or fathering a child from the first day of dosing until 3 months after the study Follow-up Visit.

11. WOCBP must be willing to use highly effective contraception measures from the first day of dosing until 3 months after the study Follow up Visit. Exclusion Criteria: Part A (Healthy participants)

1. History of following: any clinically important disease or disorder; any upper or lower respiratory tract infection during screening period; active tuberculosis or current positive result for Interferon gamma release assay at screening; clinically significant history of atopy or allergy to common allergens including house dust mite and pollens, or a history of childhood asthma.

2. Active or previous hepatitis B, hepatitis C, or Human immunodeficiency virus at the Screening Visit, and other latent or chronic infections.

3. History of severe COVID-19 (Coronavirus disease 2019) infection requiring hospitalization

4. SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2) first vaccination within 30 days prior to screening.

5. SARS-CoV-2 second or booster vaccination within 10 days of screening.

6. Unwilling to defer SARS-CoV-2 vaccination during the study period.

7. History of cancer within last 10 years (20 years for breast cancer) except for basal and squamous cell carcinoma of skin or in situ carcinoma of cervix treated and considered cured. Any history of lymphoma is not allowed.

8. Have received live or live attenuated vaccine in 4 weeks prior to randomisation.

9. History of acquired or inherited immunodeficiency disorders including but not limited to HIV, COVID-19, or taking immune replacement therapy.

10. C-reactive protein above upper limit of laboratory reference range

11. Any clinically important abnormalities in clinical chemistry, haematology or urinalysis results and abnormal vital signs at the Screening Visit.

12. Current smokers or those who have smoked or used nicotine or inhalational cannabis/marijuana products. History of alcohol abuse or drug abuse.

13. Use of any prescribed or nonprescribed medication during the 2 weeks prior to the first administration of investigational medicinal product.

14. Has received another new chemical entity.

15. History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, as judged by the investigator, or history of hypersensitivity to drugs with a similar chemical structure or class to AZD8630.

16. History of anaphylaxis to any previous biological therapy.

17. Participants who have previously received AZD8630.

Part B (Participants with Asthma):

1. History of following: any clinically important disease or disorder; any chronic respiratory disorders (except asthma) such as Chronic obstructive pulmonary disease, bronchiectasis, or IPF; clinically significant lower respiratory tract infection not resolved within 4 weeks prior to screening.

2. Acute exacerbation of asthma requiring hospitalisation and/or attendance at an emergency department and/or systemic corticosteroids within 6 weeks of randomisation.

3. History of active TB or a current positive result for IGRA at screening.

4. History of severe COVID-19 infection requiring hospitalisation.

5. SARS-CoV-2 first vaccination within 30 days prior to screening.

6. SARS-CoV-2 second or booster vaccination within 10 days of screening.

7. Confirmed COVID-19 infection during screening, prior to randomisation.

8. History of cancer within the last 10 years (20 years for breast cancer) except for basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix treated and considered cured. Any history of lymphoma is not allowed.

9. Have received live or live attenuated vaccine in the 4 weeks prior to randomisation.

10. C-reactive protein above the upper limit of laboratory reference range at screening.

11. Any clinically important abnormalities in clinical chemistry, haematology or urinalysis results, and abnormal vital signs at the Screening Visit.

12. Current smokers or those who have smoked or used nicotine or inhalational cannabis/marijuana products. History of alcohol or drug abuse.

13. Positive screen for drugs of abuse or cotinine (nicotine) prior to randomisation.

14. Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeks before first administration of study drug.

15. Use of any prescribed or nonprescribed medication during the 2 weeks prior to the first administration of study drug.

16. Use of following medicines within specified time before Screening: (a) Any biologics for asthma within 6 months prior to Screening; (b) Systemic or intranasal steroids within 4 weeks prior to Screening; (c) Xanthines, anticholinergics, or cromoglycate within 1 week prior to Screening; (d) Short acting bronchodilator other than for rescue and within 12 hours prior to Screening and Day -1 assessments.

17. History of anaphylaxis or ongoing clinically important serious allergy, or history of hypersensitivity or anaphylaxis to drugs with a similar chemical structure or class to AZD8630.

18. History of anaphylaxis to any previous biological therapy.

19. Pregnancy or intention to become pregnant during course of study, breastfeeding, or unwillingness to use a highly effective method of contraception throughout study in female participants of childbearing potential or lactating woman.

Related Conditions & MeSH terms

• Asthma

Intervention

Drug:
• AZD8630
Participants will receive Inhaled or IV doses of AZD8630 as per the arm they are assigned.
• Placebo
Participants will receive Inhaled or IV doses of placebo as per the arm they are assigned.

Locations

Country	Name	City	State
Germany	Research Site	Berlin
Germany	Research Site	Frankfurt
Germany	Research Site	Großhansdorf
Germany	Research Site	Lübeck
Germany	Research Site	Magdeburg
Germany	Research Site	Wiesbaden
United Kingdom	Research Site	Bradford
United Kingdom	Research Site	London
United Kingdom	Research Site	London
United Kingdom	Research Site	Manchester
United Kingdom	Research Site	Portsmouth
United States	Research Site	Ann Arbor	Michigan
United States	Research Site	Bakersfield	California
United States	Research Site	Boise	Idaho
United States	Research Site	El Paso	Texas
United States	Research Site	Glendale	California
United States	Research Site	Homestead	Florida
United States	Research Site	Miami	Florida
United States	Research Site	Miami	Florida
United States	Research Site	Miami	Florida
United States	Research Site	Miami	Florida
United States	Research Site	Miami	Florida
United States	Research Site	North Dartmouth	Massachusetts
United States	Research Site	Portland	Oregon
United States	Research Site	Raleigh	North Carolina
United States	Research Site	San Jose	California
United States	Research Site	Tempe	Arizona
United States	Research Site	Toledo	Ohio
United States	Research Site	White Marsh	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
AstraZeneca

Countries where clinical trial is conducted

United States,  Germany,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Part A and Part B: Number of participants with adverse events	Safety and tolerability of inhaled AZD8630 in healthy participants and participants with asthma will be assessed.	Until Follow-up (FU) Visit/Early Termination (ET) Visit (Part A: 7-day post-dose for SAD; 10-day post-last dose for MAD) and Part B: Until FU Visit/ET Visit (10-day post-last dose)
Primary	Part A (IV cohort): Time to reach maximum observed concentration (tmax) of AZD8630	tmax of AZD8630 following IV administration of single dose of AZ8630 in healthy participants will be assessed	Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)
Primary	Part A (IV cohort): Time of last observed quantifiable concentration (tlast) of AZD8630	tlast of AZD8630 following IV administration of single dose of AZ8630 in healthy participants will be assessed	Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)
Primary	Part A (IV cohort): Maximum observed serum (peak) drug concentration (Cmax) of AZD8630	Cmax of AZD8630 following IV administration of single dose of AZ8630 in healthy participants will be assessed.	Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)
Primary	Part A (IV cohort): Partial area under the serum concentration-time curve from 0 to time 24 hours post-dose [AUC(0-24)] of AZD8630	AUC(0-24) of AZD8630 following IV administration of single dose of AZ8630 in healthy participants will be assessed.	Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)
Primary	Part A (IV cohort): Area under the serum concentration curve from zero to the last quantifiable concentration (AUClast) of AZD8630	AUClast of AZD8630 following IV administration of single dose of AZ8630 in healthy participants will be assessed.	Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)
Primary	Part A (IV cohort): Area under serum concentration-time curve from zero to infinity (AUCinf) of AZD8630	AUCinf of AZD8630 following IV administration of single dose of AZ8630 in healthy participants will be assessed.	Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)
Primary	Part A (IV cohort): Terminal rate constant (?z) of AZD8630	?z of AZD8630 following IV administration of single dose of AZ8630 in healthy participants will be assessed.	Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)
Primary	Part A (IV cohort): Half-life associated with terminal slope (?z) of a semi-logarithmic concentration-time curve (t1/2?z) of AZD8630	t1/2?z) of AZD8630 following IV administration of single dose of AZ8630 in healthy participants will be assessed.	Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)
Primary	Part A (IV cohort): Mean residence time of the unchanged drug in the systemic circulation (MRTinf) of AZD8630	MRTinf of AZD8630 following IV administration of single dose of AZ8630 in healthy participants will be assessed.	Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)
Primary	Part A (IV cohort): Total body clearance of drug from serum after IV administration (CL) of AZD8630	CL of AZD8630 following IV administration of single dose of AZ8630 in healthy participants will be assessed.	Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)
Primary	Part A (IV cohort): Volume of distribution at steady state (Vss) of AZD8630	Vss of AZD8630 following IV administration of single dose of AZ8630 in healthy participants will be assessed.	Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)
Primary	Part A (IV Cohort): Volume of distribution of drug from serum after IV administration (Vz) of AZD8630	Vz of AZD8630 following IV administration of single dose of AZ8630 in healthy participants will be assessed.	Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)
Primary	Part A (IV Cohort): Number of participants with adverse events	Safety and tolerability of IV AZD8630 in healthy participants will be assessed.	Until Follow-up (FU) Visit/Early Termination (ET) Visit (7-day post-dose)
Secondary	Part A and Part B: Time to reach maximum observed concentration (tmax) of AZD8630	tmax of AZD8630 in healthy participants, including participants of Japanese and Chinese ethnicity will assessed.	Pre-dose and Post-dose: Part A- (SAD) Days 1 to 4 and FU Visit/ET Visit (7-day post-dose), (MAD) Days 1 to 17 and FU Visit/ET Visit (10-day post-last dose); Part B- Days 1 to 14, Day 28, Day 29, and FU Visit/ ET Visit (10-day post-last dose)
Secondary	Part A (A1 and A2 only): Time of last observed quantifiable concentration (tlast) of AZD8630	tlast of AZD8630 in healthy participants, including participants of Japanese and Chinese ethnicity will assessed.	Pre-dose and Post-dose: Part A- (SAD) Days 1 to 4 and FU Visit/ET Visit (7-day post-dose)
Secondary	Part A and Part B: Maximum observed serum (peak) drug concentration (Cmax) of AZD8630	Cmax of AZD8630 in healthy participants, including participants of Japanese and Chinese ethnicity will assessed.	Pre-dose and Post-dose: Part A- (SAD) Days 1 to 4 and FU Visit/ET Visit (7-day post-dose), (MAD) Days 1 to 17 and FU Visit/ET Visit (10-day post-last dose); Part B- Days 1 to 14, Day 28, Day 29, and FU Visit/ ET Visit (10-day post-last dose)
Secondary	Part A and Part B: Maximum observed serum (peak) drug concentration divided by the lung-delivered dose (LDD) [Cmax/D] of AZD8630	Cmax/D of AZD8630 in healthy participants, including participants of Japanese and Chinese ethnicity will assessed.	Pre-dose and Post-dose: Part A- (SAD) Days 1 to 4 and FU Visit/ET Visit (7-day post-dose), (MAD) Days 1 to 17 and FU Visit/ET Visit (10-day post-last dose); Part B- Days 1 to 14, Day 28, Day 29, and FU Visit/ ET Visit (10-day post-last dose)
Secondary	Part A and Part B: Concentration at the end of the dosing interval (Ctrough) [repeat dose only] of AZD8630	Ctrough of AZD8630 in healthy participants, including participants of Japanese and Chinese ethnicity will assessed.	Pre-dose and Post-dose: Part A- (MAD) Days 1 to 17 and FU Visit/ET Visit (10-day post-last dose); Part B- Days 1 to 14, Day 28, Day 29, and FU Visit/ ET Visit (10-day post-last dose)
Secondary	Part A and Part B: Partial area under the serum concentration-time curve from 0 to time 24 hours post-dose [AUC(0-24)] of AZD8630	AUC(0-24) of AZD8630 in healthy participants, including participants of Japanese and Chinese ethnicity will assessed.	Pre-dose and Post-dose: Part A- (SAD) Days 1 to 4 and FU Visit/ET Visit (7-day post-dose), and Day 1 for MAD and Part B
Secondary	Part A and Part B: Partial area under the serum concentration-time curve from 0 to time 24 hours post-dose divided by the LDD [AUC(0-24)/D] of AZD8630	AUC(0-24)/D of AZD8630 in healthy participants, including participants of Japanese and Chinese ethnicity will assessed.	Pre-dose and Post-dose: Part A- (SAD) Days 1 to 4 and FU Visit/ET Visit (7-day post-dose), and Day 1 for MAD and Part B
Secondary	Part A: Area under the serum concentration curve from zero to the last quantifiable concentration (AUClast) of AZD8630	AUClast of AZD8630 in healthy participants, including participants of Japanese and Chinese ethnicity will assessed.	Pre-dose and Post-dose: Part A- (SAD) Days 1 to 4 and FU Visit/ET Visit (7-day post-dose)
Secondary	Part A: Area under the serum concentration-time curve from time zero to time of last quantifiable drug concentration divided by the LDD (AUClast/D) of AZD8630	AUClast/D of AZD8630 in healthy participants, including participants of Japanese and Chinese ethnicity will assessed.	Pre-dose and Post-dose: Part A- (SAD) Days 1 to 4 and FU Visit/ET Visit (7-day post-dose)
Secondary	Part A and Part B: Area under serum concentration-time curve from zero to infinity (AUCinf) of AZD8630	AUCinf of AZD8630 in healthy participants, including participants of Japanese and Chinese ethnicity will assessed.	Pre-dose and Post-dose: Part A- (SAD) Days 1 to 4 and FU Visit/ET Visit (7-day post-dose), and Day 1 for MAD and Part B
Secondary	Part A and Part B: Area under the serum concentration-time curve from time zero extrapolated to infinity divided by the LDD (AUCinf /D) of AZD8630	AUCinf /D of AZD8630 in healthy participants, including participants of Japanese and Chinese ethnicity will assessed.	Pre-dose and Post-dose: Part A- (SAD) Days 1 to 4 and FU Visit/ET Visit (7-day post-dose), and Day 1 for MAD and Part B
Secondary	Part A and Part B: Area under serum concentration-time curve in the dosing interval t (AUCt) of AZD8630	AUCt of AZD8630 in healthy participants, including participants of Japanese and Chinese ethnicity will assessed.	Pre-dose and Post-dose: Part A- (MAD) Days 1 to 17 and FU Visit/ET Visit (10-day post-last dose); Part B- Days 1 to 14, Day 28, Day 29, and FU Visit/ ET Visit (10-day post-last dose)
Secondary	Part A and Part B: Area under serum concentration-time curve in the dosing interval t divided by the LDD (AUCt/D) of AZD8630	AUCt/D of AZD8630 in healthy participants, including participants of Japanese and Chinese ethnicity will assessed.	Pre-dose and Post-dose: Part A- (MAD) Days 1 to 17 and FU Visit/ET Visit (10-day post-last dose); Part B- Days 1 to 14, Day 28, Day 29, and FU Visit/ ET Visit (10-day post-last dose)
Secondary	Part A and Part B: Terminal rate constant (?z) of AZD8630	?z of AZD8630 in healthy participants, including participants of Japanese and Chinese ethnicity will assessed.	Pre-dose and Post-dose: Part A- (SAD) Days 1 to 4 and FU Visit/ET Visit (7-day post-dose), (MAD) Days 1 to 17 and FU Visit/ET Visit (10-day post-last dose); Part B- Days 1 to 14, Day 28, Day 29, and FU Visit/ ET Visit (10-day post-last dose)
Secondary	Part A and Part B: Half-life associated with terminal slope (?z) of a semi-logarithmic concentration-time curve (t1/2?z) of AZD8630	t1/2?z of AZD8630 in healthy participants, including participants of Japanese and Chinese ethnicity will assessed.	Pre-dose and Post-dose: Part A- (SAD) Days 1 to 4 and FU Visit/ET Visit (7-day post-dose), (MAD) Days 1 to 17 and FU Visit/ET Visit (10-day post-last dose); Part B- Days 1 to 14, Day 28, Day 29, and FU Visit/ ET Visit (10-day post-last dose)
Secondary	Part A and Part B: Mean residence time of the unchanged drug in the systemic circulation (MRTinf) of AZD8630	MRTinf of AZD8630 in healthy participants, including participants of Japanese and Chinese ethnicity will assessed.	Pre-dose and Post-dose: Part A- (SAD) Days 1 to 4 and FU Visit/ET Visit (7-day post-dose), (MAD) Days 1 to 17 and FU Visit/ET Visit (10-day post-last dose); Part B- Days 1 to 14, Day 28, Day 29, and FU Visit/ ET Visit (10-day post-last dose)
Secondary	Part A and Part B: Apparent total body clearance of drug from serum after extravascular administration (inhalation administration only) [CL/F] of AZD8630	CL/F of AZD8630 in healthy participants, including participants of Japanese and Chinese ethnicity will assessed.	Pre-dose and Post-dose: Part A- (SAD) Days 1 to 4 and FU Visit/ET Visit (7-day post-dose), (MAD) Days 1 to 17 and FU Visit/ET Visit (10-day post-last dose); Part B- Days 1 to 14, Day 28, Day 29, and FU Visit/ ET Visit (10-day post-last dose)
Secondary	Part A and Part B: Apparent volume of distribution following extravascular administration based on terminal phase (inhalation administration only) [Vz/F] of AZD8630	Vz/F of AZD8630 in healthy participants, including participants of Japanese and Chinese ethnicity will assessed.	Pre-dose and Post-dose: Part A- (SAD) Days 1 to 4 and FU Visit/ET Visit (7-day post-dose), (MAD) Days 1 to 17 and FU Visit/ET Visit (10-day post-last dose); Part B- Days 1 to 14, Day 28, Day 29, and FU Visit/ ET Visit (10-day post-last dose)
Secondary	Part A and Part B: Accumulation ratio based upon AUCt [Rac(AUC)] of AZD8630	Rac(AUC) of AZD8630 in healthy participants, including participants of Japanese and Chinese ethnicity will assessed.	Pre-dose and Post-dose: Part A- (MAD) Day 14; Part B- Day 28
Secondary	Part A and Part B: Accumulation ratio based upon Cmax [Rac(Cmax)] of AZD8630	Rac(Cmax) of AZD8630 in healthy participants, including participants of Japanese and Chinese ethnicity will assessed.	Pre-dose and Post-dose: Part A- (MAD) Day 14; Part B- Day 28
Secondary	Part A and Part B: Number of participants with presence of anti-drug antibodies (ADAs)	Immunogenicity of AZD8630 following single and multiple dose administration will be characterized.	Pre-dose: Part A- (SAD) Days 1 to 3 and FU Visit/ET Visit (7-day post-dose), (MAD) Days 1 to 17 and FU Visit/ET Visit (10-day post-last dose); Part B- Days 1, 7, 14, and 28, and FU Visit/ ET Visit (10-day post-last dose)
Secondary	Part B: Change from baseline in fractional exhaled nitric oxide (FeNO) levels	The PD effect of AZD8630 on FeNO versus placebo following daily inhaled AZD8630 will be assessed.	From Screening (Up to days 28 before Day 1) until Day 29 (end of the treatment visit)